{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T11:27:33Z","timestamp":1692358053633},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,6,14]],"date-time":"2009-06-14T00:00:00Z","timestamp":1244937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s11883-009-0039-1","type":"journal-article","created":{"date-parts":[[2009,6,13]],"date-time":"2009-06-13T01:25:17Z","timestamp":1244856317000},"page":"249-256","source":"Crossref","is-referenced-by-count":16,"title":["Moving toward new statin guidelines in a post-JUPITER world: Principles to consider"],"prefix":"10.1007","volume":"11","author":[{"given":"Paul M.","family":"Ridker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,14]]},"reference":[{"key":"39_CR1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"S.M. Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227\u2013239.","journal-title":"Circulation"},{"key":"39_CR2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"J.R. Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615\u20131622.","journal-title":"JAMA"},{"key":"39_CR3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J. Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301\u20131307.","journal-title":"N Engl J Med"},{"key":"39_CR4","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jama.282.20.1899","volume":"282","author":"C.R. Kumana","year":"1999","unstructured":"Kumana CR, Cheung BM, Lauder IJ: Gauging the impact of statins using number needed to treat. JAMA 1999, 282:1899\u20131901.","journal-title":"JAMA"},{"key":"39_CR5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","volume":"113","author":"R.S. Vasan","year":"2006","unstructured":"Vasan RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335\u20132362.","journal-title":"Circulation"},{"key":"39_CR6","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.amjcard.2007.09.072","volume":"100","author":"P.M. Ridker","year":"2007","unstructured":"Ridker PM, Fonseca FA, Genest J, et al., on behalf of the JUPITER Trial Study Group: Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007, 100:1659\u20131664.","journal-title":"Am J Cardiol"},{"key":"39_CR7","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"P.M. Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al., for the JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195\u20132207.","journal-title":"N Engl J Med"},{"key":"39_CR8","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","volume":"360","author":"R.J. Glynn","year":"2009","unstructured":"Glynn RJ, Danielson E, Fonseca FA, et al.: A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009, 360:1851\u20131861.","journal-title":"N Engl J Med"},{"key":"39_CR9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","volume":"319","author":"D.G. Altman","year":"1999","unstructured":"Altman DG, Andersen PK: Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999, 319:1492\u20131495.","journal-title":"BMJ"},{"key":"39_CR10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0895-7061(97)00488-3","volume":"11","author":"K.A. Pearce","year":"1998","unstructured":"Pearce KA, Furberg CD, Psaty BM, Kirk J: Cost-minimization and the number needed to treat in umcomplicated hypertension. Am J Hypertens 1998, 11:618\u2013629.","journal-title":"Am J Hypertens"},{"key":"39_CR11","unstructured":"Wiysonge CS, Bradley H, Mayosi BM, et al.: Beta-blockers for hypertension. Cochrane Database Systematic Reviews 2007, Issue 1. Art.No.:CD002003.DOI:1. 1002\/14651858. CD002003.pub2."},{"key":"39_CR12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research group","year":"1989","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research group: Final report on the aspirin component of the ongoing Physician\u2019s Health Study. N Engl J Med 1989, 321:129\u2013135","journal-title":"N Engl J Med"},{"key":"39_CR13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"P.M. Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, et al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293\u20131304.","journal-title":"N Engl J Med"},{"key":"39_CR14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","volume":"295","author":"J.S. Berger","year":"2006","unstructured":"Berger JS, Roncaglioni MC, Avanzini F, et al.: Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295:306\u2013313.","journal-title":"JAMA"},{"key":"39_CR15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nri1882","volume":"6","author":"G.K. Hansson","year":"2006","unstructured":"Hansson GK, Libby P: The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunology 2006, 6:508\u2013519.","journal-title":"Nat Rev Immunology"},{"key":"39_CR16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","volume":"336","author":"P.M. Ridker","year":"1997","unstructured":"Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973\u2013979.","journal-title":"N Engl J Med"},{"key":"39_CR17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"P.M. Ridker","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836\u2013843.","journal-title":"N Engl J Med"},{"key":"39_CR18","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"P.M. Ridker","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557\u20131565.","journal-title":"N Engl J Med"},{"key":"39_CR19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/01.CIR.0000120707.98922.E3","volume":"109","author":"W. Koenig","year":"2004","unstructured":"Koenig W, Lowel H, Baumert J, Meisinger C: C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004, 109:1349\u20131353.","journal-title":"Circulation"},{"key":"39_CR20","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","volume":"351","author":"J.K. Pai","year":"2004","unstructured":"Pai JK, Pischon T, Ma J, et al.: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599\u20132610.","journal-title":"N Engl J Med"},{"key":"39_CR21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2005.09.023","volume":"187","author":"S.M. Boekholdt","year":"2006","unstructured":"Boekholdt SM, Hack CE, Sandhu MS, et al.: C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006, 187:415\u2013422.","journal-title":"Atherosclerosis"},{"key":"39_CR22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","volume":"100","author":"P.M. Ridker","year":"1999","unstructured":"Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230\u2013235.","journal-title":"Circulation"},{"key":"39_CR23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","volume":"286","author":"M.A. Albert","year":"2001","unstructured":"Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation\/CRP Evaluation (PRINCE), a randomized trial and cohort study. JAMA 2001, 286:64\u201370.","journal-title":"JAMA"},{"key":"39_CR24","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","volume":"344","author":"P.M. Ridker","year":"2001","unstructured":"Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959\u20131965.","journal-title":"N Engl J Med"},{"key":"39_CR25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","volume":"98","author":"P.M. Ridker","year":"1998","unstructured":"Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998, 98:839\u2013844.","journal-title":"Circulation"},{"key":"39_CR26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"P.M. Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20\u201328.","journal-title":"N Engl J Med"},{"key":"39_CR27","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","volume":"45","author":"P.M. Ridker","year":"2005","unstructured":"Ridker PM, Morrow DA, Rose LM, et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dl and C-reactive protein <2 mg\/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45:1644\u20131648.","journal-title":"J Am Coll Cardiol"},{"key":"39_CR28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","volume":"114","author":"D.A. Morrow","year":"2006","unstructured":"Morrow DA, de Lemos JA, Sabatine MS, et al.: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006, 114:281\u2013288.","journal-title":"Circulation"},{"key":"39_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","volume":"352","author":"S.E. Nissen","year":"2005","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29\u201338.","journal-title":"N Engl J Med"},{"key":"39_CR30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"P.M. Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al.: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective case study of the JUPITER trial. Lancet 2009, 373:1175\u20131182.","journal-title":"Lancet"},{"key":"39_CR31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","volume":"107","author":"P.M. Ridker","year":"2003","unstructured":"Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391\u2013397.","journal-title":"Circulation"},{"key":"39_CR32","unstructured":"CRP and Statins for Primary Prevention of Coronary Artery Disease. The Medical Letter 2008, 50: (December 15\/29, issue 1301\/1302)."},{"key":"39_CR33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1373\/clinchem.2008.115899","volume":"55","author":"NACB LMPG Committee Members","year":"2009","unstructured":"NACB LMPG Committee Members: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009, 55:378\u2013384.","journal-title":"Clin Chem"},{"key":"39_CR34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","volume":"297","author":"P.M. Ridker","year":"2007","unstructured":"Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007, 297:611\u2013619.","journal-title":"JAMA"},{"key":"39_CR35","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","volume":"118","author":"P.M. Ridker","year":"2008","unstructured":"Ridker PM, Paynter NP, Rifai N, et al.: C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds Risk Score for Men. Circulation 2008, 118:2243\u20132251.","journal-title":"Circulation"},{"key":"39_CR36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMsa0810119","volume":"360","author":"A.B. Haynes","year":"2009","unstructured":"Haynes AB, Weiser TG, Berry WR, et al.; Safe Surgery Saves Lives Study Group: A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med 2009, 360:491\u2013499.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-009-0039-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-009-0039-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-009-0039-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:35:35Z","timestamp":1559417735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-009-0039-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,14]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1007\/s11883-009-0039-1","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,14]]}}}